NCT00193232View on ClinicalTrials.gov

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

February 28, 2007

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

DRUG

Bortezomib

Sponsors
All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER